Drug Development Pharma - August 4, 2014
Medivir licenses respiratory syncytial virus drug program
The company has entered a license agreement with Boehringer Ingelheim International GmbH for exclusive, global rights to a drug program for the treatment and prevention of RSV infection. The program includes novel compounds that inhibit the RSV fusion protein, which is a key mediator of viral entry into host cells and a target for new […]
Drug Development Pharma - June 10, 2014
Medivir launches Olysio in the Nordic countries
Medivir has announced that its NS3/4A protease inhibitor Olysio will be available in all of the Nordic countries within the next few weeks. Treatment with Olysio began in Sweden in late May, followed by Finland and Denmark, where the first patients recently began their treatment. “It is immensely gratifying to now be able to offer a new […]
Collaboration - June 10, 2014
Beactica and Medivir in drug discovery collaboration
The Swedish fragment-based drug discovery company has entered into an agreement with Medivir. Under the agreement, Beactica will use its proprietary discovery platform to identify novel hits against a disease-relevant protease of therapeutic interest to Medivir. Financial terms of the agreement have not been disclosed. “We are pleased that Medivir has selected Beactica to advance one […]
In a new job - May 9, 2014
Anders Ekblom joins board at Medivir
As the company recently held its annual general meeting a new chairman was elected as well as three new members, including Anders Ekblom, former CEO at AstraZeneca AB. Niklas Prager, former CEO at Pfizer AB and Bertil Samuelsson, former Chief Scientific Advisor at Medivir, also were elected into the board. Anders Hallberg, Anna Malm Bernsten, Björn […]
Drug Development Pharma - March 25, 2014
Russian yes to simeprevir
The Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, announces Medivir. Russia will be the first country within EMEA to gain access to simeprevir. “The Russian approval is another important event for simeprevir and provides the hepatitis C patients in Russia with a new HCV treatment” […]
Drug Development Pharma - March 24, 2014
Simeprevir receives positive CHMP opinion
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending Marketing Authorisation in the European Union for the use of simeprevir in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients. “The recommendation is one additional step in the global strategy that our […]
